HAS ASSESSMENT OUTCOMES | FRANCE PHARMA NEWS
May 20, 2022 HAS gave a favorable opinion for Xeljanz in patients with polyarticular juvenile idiopathic arthritis HAS given position...
iPharmaCenter
Putting patients at center
NEWS
NICE ASSESSMENT OUTCOMES
May 25, 2022 Keytruda was recommended for a rare form of TNBC NICE has published the final draft recommendation, in which Keytruda...
2022 FDA Drug Approvals
June 17, 2022 Skyrizi received FDA approval for Crohn's Disease in adults. AbbVie has announced that the U.S. Food and Drug...
Pharmaceutical Companies Deals and acquisitions | Sanofi | Novo Nordisk
May 10, 2022 Pfizer will acquire Biohaven Pharmaceuticals. Pfizer and Biohaven Pharmaceuticals announced that they had entered an...
Spinal Muscular Atrophy News
April 29, 2022 Evrysdi improved survival and motor milestones in infants with type 1 SMA Roche announced that Evrysdi (risdiplam)...
TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022
REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES 2022 1 CHF = 1.04 USD Merck revenues include only pharmaceuticals (excluding animal health)...
Expected best selling pharmaceuticals/drugs of 2022
EXPECTED BEST SELLING PRODUCTS OF 2022 Comirnaty (Pfizer) Comirnaty is a messenger RNA (mRNA) based COVID vaccine developed by Pfizer and...
China Drug Approvals | NMPA Drug Approvals | Pharma | Healthcare | China
April 15, 2022 Tislelizumab was approved in China as second-line therapy for esophageal squamous cell carcinoma BeiGene announced that...
Health Canada Drug Approvals | Healthcare and Pharmaceutical News of Canada | News | Blogs | Canada
Health Canada approved Rybrevant for EGFR exon insertion mutation NSCLC. Janssen announced that Health Canada issued a Notice of...
REGIONAL NEWS | REGULATORY APPROVALS | HEALTHCARE NEWS
HEALTH TECHNOLOGY ASSESSMENT OUTCOMES
HEALTHCARE SYSTEMS
HEALTHCARE SYSTEM IN CHINA
Overview of China healthcare system China achieved universal health coverage in 2011. The urban employed is covered via an...
Drug pricing and reimbursement in Germany | Health Technology Assessment in Germany
It is mandatory to have health insurance in Germany. Statutory Health Insurance covers 90% of the German population, and the rest, 10%,...
Why the cost of prescription drugs is high in the US?
The United States spends more on prescription drugs compared to other developed nations. On average, the United States spends as much as...
China released the 2022 NDRL list, Chinese pharma benefited from the list
China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs. Reuters reported a...
JAPAN HEALTHCARE SYSTEM
INTRODUCTION Japan has a population of 126 million, nearly twice the size of the UK population. Japan is the third-largest economy. The...
UNITED STATES HEALTHCARE SYSTEM
The USA is a public and private healthcare system. Medicare is a federal program which funds for the healthcare for adults higher than 65...
CONFERECES
CONFERENCES
European Academy of Neurology (EAN) Congress 2022 | News | Updates | iPharmaCenter
NOVARTIS - KESIMPTA NOVARTIS PRESENTED STRONG EXTENSION STUDY DATA OF KESIMPTA AT THE EAN 2022 CONGRESS Novartis announced new data from...
EHA 2022 | News | Updates | Europe Health Conferences | Pharma | Healthcare | cancer | iPharmaCenter
JANSSEN Teclistamab in multiple myeloma Janssen Pharmaceuticals announced the Phase 1b TriMM-2 study results in patients with relapsed or...
EULAR 2022
JANSSEN TREMFYA FOR PSORIATIC ARTHRITIS Janssen presented the new and long-term data of DISCOVER-1, DISCOVER-2, and COSMOS studies,...
ASCO 2022 | News | Updates | Roche | BMS |
ROCHE Glofitamab for diffuse large B-cell lymphoma (DLBCL) Roche announced that new pivotal data on glofitamab will be presented at ASCO...
ESMO BREAST CANCER 2022 | NEWS | UPDATES | EUROPE
NOVARTIS KISQALI (ribociclib) Novartis presented the updated study results of the MONALEESA-3 trial. Kisqali plus fulvestrant showed a...
ASCO GU 2022 | American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
JANSSEN Niraparib, abiraterone acetate, prednisone combination Janssen announced the initial results from the Phase 3 MAGNITUDE study...